Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

AstraZeneca (NASDAQ:AZN) reported its Q1 earnings results on Friday, April 29, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings AstraZeneca reported an EPS of $1.89.

Benzinga

AstraZeneca faces revenue hit as Covid-19 vaccine demand falls

Pharmaceutical giant has also announced plans to open a new research and development centre in Boston, Massachusetts

Evening Standard

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

AstraZeneca Plc's (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022. Core EPS came in at $1.89,…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Sales of Covid vaccine set to decline as demand wanes, AstraZeneca predicts

The business has already seen a significant drop in the use of its vaccines to Europe.

The Independent UK

How To Attend AstraZeneca Q1 2022 Earnings Conference Call

AstraZeneca (NASDAQ:AZN) will host a conference call at 06:45 AM ET on April 29, 2022, to discuss Q1 2022 earnings results. How to Attend AstraZeneca (AZN) Conference Call Follow this link to access the live webcast.

Benzinga

Latest data shows significant rise in Covid deaths in England and Wales for third week in a row

Deaths involving Covid-19 are up 13 per cent on last week, the latest data shows

Manchester Evening News

If You Invested $100 In AstraZeneca 5 Years Ago, Here's How Much You Would Have Today

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.24% on an annualized basis producing an average annual return of 17.72%. Currently, AstraZeneca has a market capitalization of $213.61 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Covid booster gives long-lasting protection, study finds

'The longer-term protection against hospitalisation and death is perhaps the most important factor for future booster programmes'

Wales Online

Third Covid-19 vaccine dose offers ‘prolonged immune response’ – UK-wide study

The study compared immune responses to seven vaccines used as a booster 28 days after two initial doses.

The Independent UK

AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals

AstraZeneca plc (NASDAQ:AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo. There were no…

Benzinga

Covid-19 vaccine maker Oxford Biomedica pauses production as AstraZeneca partnership reviewed

Shares in the FTSE 250 company slumped as much as 10% as it warned revenues will be lower this year than last

Evening Standard

The Valneva COVID vaccine has been approved for use in the UK – here's what the evidence says

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new COVID vaccine. VLA2001 is manufactured by French pharmaceutical company Valneva for use in the UK and was approved on April 14 for use in adults between the ages of 18 and 50 for first and second doses.

The Conversation

Covid vaccine developed in West Lothian is approved

It is the sixth Covid-19 vaccine to be granted an MHRA authorisation for use in Britain

Daily Record

GlaxoSmithKline and AstraZeneca secure victories with US drug regulator

GlaxoSmithKline’s drug aimed at chronic kidney disease patients with anaemia and AstraZeneca’s lung cancer treatment have both moved a step closer to getting the green light

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Daily Mirror

Nasal sprays and pills could be 'game-changer' in future fight against Covid-19

There's been an explosion in vaccine research - as an oral Covid-19 inoculation is tested in the US, Jane Symons asks if no-jab vaccines could be the future of immunisation

Reuters

Thai politician indicted for royal insult over vaccine speech

A prominent Thai politician faces up to 20 years in prison following his indictment on Monday for insulting the king and violating a cyber law, after he criticised the government for over-reliance on a royal-owned firm to supply COVID-19 vaccines.

The Independent UK

How Russia’s Ukraine invasion doomed the Sputnik V coronavirus vaccine

Manufacturing of the vaccine has slowed and further research is stalled

The Independent UK

India extends COVID-19 booster shots to all adults

India has begun offering booster doses of COVID-19 vaccine to all adults but is limiting free shots at government centers to front-line workers and people over age 60

Get all your
news in one place.

100’s of premium titles.
One news app.

Bangkok Post

Evusheld procurement plan gets CCSA approval

The Centre for Covid-19 Situation Administration (CCSA) has approved a plan to procure a long-acting coronavirus antibody cocktail for people with poor immune systems who cannot be vaccinated.

Benzinga

AstraZeneca Bets $25M On Preclinical Bispecific Antibody

Harbour BioMed has announced a global out-license agreement with AstraZeneca plc (NASDAQ:AZN) for CLDN18.2xCD3 bispecific antibody (HBM7022). HBM7022 is a novel bispecific antibody generated from HBM's HCAb Based Immune Cell Engagers (HBICE) Platform. HBM7022 is currently in the preclinical stage, which crosslinks tumor cells and T cells by targeting a tumor-associated antigen (Claudin18.2) and…

Benzinga

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.32% on an annualized basis producing an average annual return of 18.01%. Currently, AstraZeneca has a market capitalization of $214.04 billion.

Benzinga

AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease

AstraZeneca Plc (NASDAQ:AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG). Ultomiris demonstrated long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life sustained through 60 weeks. Ultomiris was also well tolerated throughout…

Salon

Why Big Pharma loves Tim Scott

During the second half of 2021, Scott was the top recipient of drug campaign cash in Congress

Tribune News Service

Big Pharma is betting on bigger political ambitions from Sen. Tim Scott

Sen. Tim Scott, a rising star in the Republican Party with broad popularity in his home state of South Carolina, is getting showered with drug industry money before facing voters this fall.

1 … 15 16 17 18

People

Thanakorn Wangboonkongchana

101 stories

Pascal Soriot

58 stories

Thanathorn Juangroongruangkit

48 stories

Taweesilp Visanuyothin

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Food and Drug Administration

325 stories

World Health Organisation

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.